Mike Dolph - Concepedia

Author

Mike Dolph

Novartis (United States)

Also Known As

M Dolph, M. Dolph, Mike Dolph

Publications

128

Citations

H-Index

Concepts

All Affiliations

Novartis (United States)Tris Pharma (United States)University of Glasgow Novartis (United Kingdom)

About

Mike Dolph is an author at Novartis (United States) specializing in medicine, hematology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	23
2	Hematology	2	2	23
3	Health Sciences	1	1	13
4	Health Policy	1	1	13
5	Clinical Trials	1	1	13

Mike Dolph

Publications

116

Citations

H-Index

Page 1

	Year	Citations
Systematic review of health state utility values for acute myeloid leukemia Anna Forsythe, Patricia Brandt, Mike Dolph, ClinicoEconomics and Outcomes Research	2018	31
Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2&minus; advanced breast cancer Gabriel Tremblay, David Chandiwana, Mike Dolph, Cancer Management and Research	2018	25
Cost-effectiveness analysis for midostaurin versus standard of care in acute myeloid leukemia in the United Kingdom Gabriel Tremblay, Mike Dolph, Sachin Patel, Cost Effectiveness and Resource Allocation	2018	15
The Cost-effectiveness of Eltrombopag for the Treatment of Immune Thrombocytopenia in the United States Gabriel Tremblay, Mike Dolph, Anuja Roy, Clinical Therapeutics ThrombopoiesisThrombosisVenous ThrombosisHealth SciencesHealth Policy	2020	13
Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopenia Gabriel Tremblay, Mike Dolph, Menaka Bhor, ClinicoEconomics and Outcomes Research	2018	12
Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopenia Gabriel Tremblay, Mike Dolph, Menaka Bhor, ClinicoEconomics and Outcomes Research	2018	10
Cost-effectiveness of midostaurin in the treatment of newly diagnosed FLT3-mutated acute myeloid leukemia in France Gabriel Tremblay, C Cariou, Christian Récher, The European Journal of Health Economics Hematological MalignancyOncologyMixed-phenotype Acute LeukemiaMalignant Blood DisorderHematology	2020	10

Page 1